KKR Sells Four Points Flex by Sheraton Portfolio in Japan

KKR Sells Four Points Flex by Sheraton Portfolio in Japan

TOKYO–(BUSINESS WIRE)–
Global investment firm KKR today announced that funds managed by KKR have completed the sale of a portfolio of 16 hotels across Japan operating under the Four Points Flex by Sheraton brand to a leading global institutional investor.

Located in 11 cities across major tourist destinations such as Greater Tokyo, Osaka, Kyoto, and Fukuoka, the portfolio is conveniently situated close to prime transportation links, world-class dining, and key business and leisure districts, providing consumers with quality, affordable accommodation amid a sustained rebound in international and domestic tourism.

KKR acquired the portfolio from Unizo Holdings in 2024, and subsequently undertook a comprehensive renovation and repositioning program. In strategic partnership with Marriott International, KKR launched the Four Points Flex by Sheraton brand in Asia Pacific, providing the hotels with access to Marriott’s global distribution network and Marriott Bonvoy loyalty base.

KJRM, one of Japan’s largest asset management companies, which KKR acquired in 2022, acted as the portfolio’s asset manager from acquisition through renovation and repositioning, and will continue to serve as the asset manager for the portfolio following the transaction. KJRM intends to work with the new owner to add further stabilized Japan hotel investments to the portfolio over time.

K+ Hospitality Management, KKR’s dedicated hotel operating platform in Japan, will continue operating the hotels following the sale, providing a platform for potential future growth.

Since acquiring the portfolio, KKR has undertaken a range of value creation initiatives, including:

  • Executing a comprehensive renovation program to modernize the assets and deliver a consistent, welcoming guest experience throughout the portfolio;

  • Enhancing the management team and reorganizing the corporate structure of the underlying hotel operating platform to strengthen oversight and decision-making;

  • Introducing institutional budgeting, reporting, and revenue management practices to optimize pricing and occupancy;

  • Strengthening the organization and enhancing HR practices to support long-term operational performance; and

  • Leveraging KJRM’s asset management capabilities and K+ Hospitality Management’s operating expertise to support the renovation, repositioning, and ongoing performance of the portfolio.

David Cheong, Head of Acquisitions for KKR’s Asia Real Estate team, said, “We saw an opportunity to reposition this portfolio for Japan’s growing demand for high-quality, accessible accommodation, and we’re proud of what we’ve built with Marriott, leveraging KJRM and K+ Hospitality’s capabilities. We look forward to continuing to grow both platforms, and pursuing new opportunities across Japan’s hospitality sector. Japan remains one of the most important markets for our real estate strategy, and we have strong conviction in the long-term fundamentals of the country’s hospitality and broader real estate sector.”

KKR continues to be highly active in Japan’s real estate sector, which today includes a portfolio of Sapporo Real Estate – a diverse mix of commercial, office, and residential assets including Yebisu Garden Place in Tokyo – as well as multifamily properties and office assets across Japan, among others.

Additional details of the transaction have not been disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media Contacts

Wei Jun Ong

+65 6922 5813

[email protected]

Samuel Brustad

+81 90 7094 2523

[email protected]

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Professional Services Commercial Building & Real Estate Lodging Finance Construction & Property Asset Management Travel

MEDIA:

Logo
Logo

CenterPoint Energy Declares Regular Common Stock Dividend of $0.2400

CenterPoint Energy Declares Regular Common Stock Dividend of $0.2400

HOUSTON–(BUSINESS WIRE)–CenterPoint Energy, Inc.’s (NYSE: CNP) Board of Directors today declared a regular quarterly cash dividend of $0.2400 per share on the issued and outstanding shares of Common Stock payable on December 10, 2026, to shareholders of record at the close of business on November 19, 2026.

About CenterPoint Energy

As the only investor-owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

For more information, contact
Communications
[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Utilities Energy

MEDIA:

Logo
Logo

PLAYSTUDIOS Announces 1-for-10 Reverse Stock Split and Provides an Update on Stock Repurchases

PLAYSTUDIOS Announces 1-for-10 Reverse Stock Split and Provides an Update on Stock Repurchases

Class A Common Stock Expected to Begin Trading on a Split-Adjusted Basis on October 1, 2026

LAS VEGAS–(BUSINESS WIRE)–
PLAYSTUDIOS, Inc. (Nasdaq: MYPS) (the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Reverse Stock Split”) of its Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), and Class B common stock, par value $0.0001 per share (the “Class B Common Stock” and, together with the Class A Common Stock, the “Common Stock”).

The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on September 30, 2026 (the “Effective Time”). The Company’s Class A Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on October 1, 2026 under the existing ticker symbol “MYPS.”

The Company also announced that, during the third quarter of 2026 through September 24, it has repurchased approximately 4.3 million shares of Class A Common Stock for an aggregate purchase price of $3.0 million, or an average price of approximately $0.71 per share, in open-market transactions pursuant to its existing Rule 10b5-1 share repurchase plan. The Company continues to evaluate opportunities to return capital to stockholders, including through additional share repurchases under its existing authorization and other potential capital return initiatives.

At the Effective Time, every 10 shares of Class A Common Stock issued and outstanding immediately prior to the Effective Time will automatically be combined into one share of Class A Common Stock, and every 10 shares of Class B Common Stock issued and outstanding immediately prior to the Effective Time will automatically be combined into one share of Class B Common Stock. The Reverse Stock Split will not change the par value of the Common Stock or the number of authorized shares of Class A Common Stock or Class B Common Stock. The Reverse Stock Split will apply equally to both classes of Common Stock and will not change the relative voting rights of the holders of Class A Common Stock and Class B Common Stock.

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive cash in lieu of the fractional share in an amount equal to the fraction multiplied by the official closing price of the Class A Common Stock on The Nasdaq Capital Market on September 30, 2026, as adjusted for the Reverse Stock Split.

Proportionate adjustments will be made, as applicable and in accordance with the terms of the Company’s equity plans, to the number of shares subject to outstanding equity awards, the applicable exercise prices of outstanding stock options, and the number of shares available for future issuance under the Company’s equity plans.

The Reverse Stock Split was approved by the Company’s stockholders at the Company’s 2026 Annual Meeting of Stockholders and is being implemented to support the Company’s efforts to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Registered stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares or cash in lieu of fractional shares, if applicable. Stockholders who hold shares through a broker, bank or other nominee will have their positions adjusted to reflect the Reverse Stock Split and will receive cash in lieu of any fractional share interests through their broker, bank or other nominee, subject to the applicable intermediary’s processing procedures. The new CUSIP number for the Class A Common Stock following the Reverse Stock Split will be 72815G306.

Continental Stock Transfer & Trust Company, the Company’s transfer agent, will act as the exchange agent for the Reverse Stock Split. Registered stockholders holding certificated shares will receive instructions regarding the exchange of their shares and should not submit their certificates until instructed to do so.

About PLAYSTUDIOS

PLAYSTUDIOS (Nasdaq: MYPS), creator of the groundbreaking myVIP loyalty program, is a publisher and developer of award-winning mobile games, including the iconic Tetris® mobile app, Tetris Block Party, Solitaire, Spider Solitaire, Sudoku, and its casino-style games such as POP! Slots, myVEGAS Slots, myVEGAS Blackjack, myKONAMI Slots, and myVEGAS Bingo. The myVIP loyalty platform offers its members the richest rewards in gaming and enables them to earn real-world rewards from a global collection of iconic hospitality, entertainment, and leisure brands. playAWARDS partners include MGM Resorts International, Norwegian Cruise Lines, Royal Caribbean Cruise Lines, Virgin Voyages, Topgolf, and Cirque du Soleil, among others. Founded by a team of veteran gaming, hospitality, and technology entrepreneurs, PLAYSTUDIOS apps combine the best elements of popular casual games with compelling real-world benefits. To learn more about PLAYSTUDIOS, visit playstudios.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing and implementation of the Reverse Stock Split, the expected commencement of trading on a split-adjusted basis, the Company’s efforts to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, and the Company’s potential future share repurchases and other capital return initiatives. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ materially include, among others, changes in market conditions, fluctuations in the market price of the Company’s Class A Common Stock, the Company’s ability to satisfy Nasdaq’s continued listing requirements, the availability of capital for future share repurchases or other capital return initiatives, and the other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

PLAYSTUDIOS Contacts

Investor Relations

[email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Entertainment Technology Mobile Entertainment Software Electronic Games Casino/Gaming

MEDIA:

HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit with SBS Law

HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Honeywell Aerospace Inc. (“Honeywell Aerospace” or “the Company”) (NASDAQ: HONA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of HONA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: June 29, 2026 and September 1, 2026

DEADLINE: November 23, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Honeywell Aerospace’s supply chain resulted in a relatively small number of suppliers having a “disproportionate impact” on its sales. The Company’s key suppliers were impacted by supply constraints. The Company was under investigation for alleged violations of the False Claims Act related to government cybersecurity requirements. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Honeywell Aerospace, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up to an additional 3,937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.” The offering is expected to close on September 28, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering. LifeSci Capital is acting as a book-running manager for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at [email protected].

In addition, AbbVie has agreed to purchase, in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), a number of shares of ADARx’s common stock that would result in AbbVie owning approximately 4.9% of ADARx’s outstanding shares of common stock following the closing of the initial public offering and the concurrent private placement, at a price of $17.00 per share; provided, however, that in no event would AbbVie purchase more than $100.0 million in shares of common stock. The aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, are expected to be approximately $535.2 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. The concurrent private placement is also scheduled to close on September 28, 2026, subject to the satisfaction of customary closing conditions. The closing of the concurrent private placement is contingent and conditioned upon consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

Forward-Looking Statements

The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can,” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern ADARx’s strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to ADARx’s expected gross proceeds from the initial public offering and concurrent private placement, the expected date for ADARx’s common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering and concurrent private placement. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. ADARx’s expectations, beliefs and projections are expressed in good faith and ADARx believes there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. ADARx undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.



Contacts

Investors: [email protected]

Media: [email protected]

ComEd Hourly Pricing Program Reaches Record Participation, While Saving Customers $63 Million Since 2007

ComEd Hourly Pricing Program Reaches Record Participation, While Saving Customers $63 Million Since 2007

More than 70,000 residential customers enrolled in ComEd’s Hourly Pricing program, taking advantage of lower energy supply prices by shifting energy use to times when electricity demand is lower on the grid

CHICAGO–(BUSINESS WIRE)–
ComEd today announced that customers participating in its Hourly Pricing program have saved more than $63 million on electricity supply costs to date while helping reduce energy demand during periods of peak electricity use. The program has reached a record 70,000 residential customers following its largest single year of growth since launching in 2007. More than 80 percent of participants reduced their electricity supply costs compared with ComEd’s standard fixed-price supply rate in 2025.

ComEd’s Hourly Pricing offers customers the unique opportunity to pay electricity supply prices that vary by hour based on the real-time market conditions. By shifting energy-intensive activities such as charging electric vehicles, running appliances and cooling homes to lower-priced hours, participants can save on their monthly energy bills. The program also helps reduce demand during periods of peak electricity use, creating broader benefits for the electric system and electricity markets.

“Keeping energy bills as low as possible and helping customers manage their energy costs continues to be among the highest priorities,” said Ajit Apte, senior vice president of customer operations for ComEd. “The success of Hourly Pricing demonstrates that when customers have tools and information to make informed energy decisions, they can save money, reduce strain on the electric grid and contribute to a cleaner energy future. As participation continues to grow, especially among electric vehicle owners and customers with solar generation, programs like Hourly Pricing can help customers take advantage of the benefits of an increasingly electrified future.”

Hourly Pricing experienced unprecedented growth during 2025, adding over 16,000 new participants. Last year, the program delivered nearly $6.3 million in cumulative electricity supply savings to participating customers. Participants in ComEd’s Hourly Pricing program saved an average of $166 on annual electricity supply charges in 2025.

Growth was fueled in part by increasing adoption of electric vehicles and customer-owned solar and battery storage. In 2025, the number of participants with solar generation increased 109 percent to more than 8,000 customers, while self-reported electric vehicle and plug-in hybrid ownership among participants increased 69 percent to almost 22,000 customers. Nearly 30 percent of all 2025 enrollments were connected to ComEd’s Electric Vehicle Charger and Installation Rebate Program.

“I am retired and can alter my electric usage easily by rearranging when I do tasks throughout the day. When living on a reduced income, every opportunity to lower my electric bill is welcome. Thanks for making it possible,” said Deb H., a ComEd Hourly Pricing participant since 2019.

Hourly Pricing benefits extended beyond participant savings in 2025. Independent analysis found that the program generated approximately $22.8 million in net benefits across the PJM regional power system, which manages the flow of wholesale electricity across the District of Columbia and 13 states, including Illinois. This occurred when participants shifted electricity use away from high-demand periods, which helped reduce strain on the grid, lower capacity costs and reduce wholesale electricity prices for consumers across the broader market.

The program also generated nearly $1 million in environmental benefits through reductions in carbon dioxide, sulfur dioxide and nitrogen oxide emissions and achieved an estimated aggregate peak load reduction of nearly 14 megawatts (MW), demonstrating how smart energy management tools can help customers lower costs while supporting a more efficient and reliable electric grid.

“We’re proud to be a long-term partner in ComEd’s Hourly Pricing,” said Dr. Anne Evens, CEO of Elevate, which administers the program. “Participants saved an average of $166 on their annual supply charges, a powerful reminder that small changes when we use energy can make a big difference. We look forward to seeing this program help even more households lower their energy bills in the years ahead.”

ComEd continues to expand the range of time-varying rate options available to help customers manage electricity supply costs. While Hourly Pricing allows participants to pay market-based electricity supply prices that change every hour, ComEd’s newer Time of Day Pricing program offers predictable pricing structures with defined lower-cost periods for shifting energy use.

For customers who may be struggling to keep up with energy bills, ComEd also offers the Smart Assistance Manager (ComEd.com/SAM), a free online tool designed to help customers quickly identify financial assistance programs, payment arrangements, bill-management options and energy-saving programs that may fit their individual circumstances.

Customers interested in learning more about Hourly Pricing and determining whether the program may be a good fit for their household can visit ComEd.com/HourlyPricing.

ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ: EXC), a Fortune 200 company and one of the nation’s largest utility companies, serving more than 10.7 million electricity and natural gas customers. ComEd powers the lives of more than 4.2 million customers across northern Illinois, or 70 percent of the state’s population. For more information, visit ComEd.com, and connect with the company on Facebook, Instagram, LinkedIn, X and YouTube.

ComEd

Media Relations

312-394-3500

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: EV/Electric Vehicles Utilities Oil/Gas Sustainability Alternative Energy Consumer Energy Automotive State/Local Environment Green Technology Other Consumer Public Policy/Government

MEDIA:

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer’s disease exhibit markedly different biological responses during treatment with lecanemab.

Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar’s NULISAseq™ CNS 120 panel to measure 130 plasma proteins spanning amyloid and tau pathology, inflammation, neurodegeneration and synaptic function. Researchers profiled 2,385 samples from 1,967 participants using just 25 microliters of plasma per sample, including patients receiving lecanemab as part of standard clinical care at the Washington University Memory Diagnostic Center and untreated comparison groups from the Knight Alzheimer Disease Research Center.

“Anti-amyloid therapies are now part of routine care, but until now we have had a very narrow window into what is actually happening biologically in the patients receiving them,” said Carlos Cruchaga, PhD, Professor of Psychiatry and director of the NeuroGenomics and Informatics Center at Washington University School of Medicine, and co-senior author of the study. “Our findings show that Alzheimer’s disease and neurodegeneration biomarkers have unique trajectories that capture specific biological process associated with treatment response.”

The proteins associated with amyloid clearance were largely different from those associated with subsequent cognitive decline. The findings show that amyloid clearance and cognitive response reflect different biological processes, helping explain why clearing amyloid does not produce the same degree of clinical benefit in every patient, a pattern observed both in this cohort and across anti-amyloid trials.

Additionally, among 197 patients treated with lecanemab, 34 of the 130 biomarkers measured significantly changed with the number of infusions received, and they did not all move in the same direction. Among the proteins that most strongly distinguished these patients from controls, the brain-derived forms of tau consistently outperformed the same proteins circulating in the periphery, accounting for four of the top five both before treatment and at the last infusion stage. Separating tau that originates in the brain from its systemic counterpart requires both high specificity for the brain-derived form and the sensitivity to detect it at very low concentrations. Measuring these variants alongside more than 100 additional proteins in a single sample is what allowed the investigators to track pathology and treatment response in one assay.

“This study shows why measuring one or two biomarkers is not enough to understand what is happening during treatment and why ultra-high sensitivity matters,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Alamar’s precision proteomics platform gives researchers a much richer picture of treatment response and helps us understand why patients with the same diagnosis can have very different outcomes.”

About Alamar Biosciences 
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

Forward Looking Statements 
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Alamar platform’s capabilities, performance and impact, including its ability to provide richer insights into the treatment response of patients receiving anti-amyloid antibody therapy in real-world clinical practice. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on , 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 

Media Contact: 
[email protected] 

Investor Contact: 
[email protected] 



50-Acre Puget Sound Multifamily Asset Sale Brokered by Institutional Property Advisors

50-Acre Puget Sound Multifamily Asset Sale Brokered by Institutional Property Advisors

BOTHELL, Wash.–(BUSINESS WIRE)–Institutional Property Advisors (IPA), a division of Marcus & Millichap (NYSE:MMI) dedicated to serving the company’s institutional clients, announced today the sale of Griffis North Creek, a 524-unit multifamily property in Bothell, Washington.

“Griffis North Creek is an institutional-quality asset situated on nearly 50 acres of land in one of the region’s most dynamic employment hubs, a combination that is increasingly difficult to replicate in today’s market,” said Giovanni Napoli, IPA executive managing director investments. “Griffis Residential completed high-end renovations to 43% of the units and common areas, providing the buyer with a strong foundation and a clear path to upgrade the remaining units. The buyer intends to build on these improvements by continuing renovations throughout the property.” Napoli, Philip Assouad, Ryan Harmon, Nick Ruggiero, and Anthony Palladino of IPA represented the seller, Griffis Residential, and procured the buyer, GID.

“Seattle’s Eastside continues to stand out for its concentration of high-paying employment and the long-term demand drivers that support multifamily housing,” said Andrew Leahy, national director of IPA Multifamily. “At the same time, development constraints and the cost of new construction make communities of this scale increasingly difficult to replicate, strengthening the competitive position of established assets such as Griffis North Creek.”

The property is in Bothell’s tech and biomedical corridor within the Seattle area’s Eastside region in a neighborhood with average annual household income over $142,000. Microsoft, Amazon, Google, Meta, and Apple have offices within a short drive. The Canyon Park and Parklands North Creek business centers are nearby, and Alderwood shopping center provides nearby retail and dining options.

Built in 1999, Griffis North Creek is bordered by greenbelts on two sides, and a greenbelt and creek run through the grounds. The property is composed of 23 three-story buildings with stone façades and iron railings. Community amenities include wooded walking trails, pagodas, footbridges, a renovated central clubhouse and lounge, a heated swimming pool and spa, two playgrounds, and a fenced-in dog park. All units have a private deck or patio, full-size washers and dryers, walk-in closets, and linen closets. The unit mix is one-, two- and three-bedroom apartments with an average size of 835 square feet.

About Institutional Property Advisors (IPA)

Institutional Property Advisors (IPA) is a division of Marcus & Millichap (NYSE: MMI), a leading commercial real estate services firm in North America. IPA’s combination of real estate investment and capital markets expertise, industry-leading technology, and acclaimed research offers customized solutions for the acquisition, disposition and financing of institutional properties and portfolios. For more information, please visit www.institutionalpropertyadvisors.com

About Marcus & Millichap

Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. Marcus & Millichap closed 8,818 transactions with a sales volume of $50.8 billion in 2025. The company had 1,808 investment sales and financing professionals in more than 80 offices at year end.

Gina Relva, VP of Public Relations

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo

Faraday Future Announces Details for Its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two Upstream Partner Session & Industry Ecosystem Co-Creation Session to be Held on Sept. 29

Faraday Future Announces Details for Its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two Upstream Partner Session & Industry Ecosystem Co-Creation Session to be Held on Sept. 29

  • On September 28-30, FF will hold Its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two Upstream Partner Session & Industry Ecosystem Co-Creation Session at the International Conference on Intelligent Robots and Systems (IROS) in Pittsburgh, PA.

  • FF has invited more than 10 global partners to participate in the event and share their perspectives on the EAI robotics industry and the “Built in USA” initiative.

  • A video of the event will go live at 5:00 p.m. PDT on Sept. 29 at www.ff.com.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced details for its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two Upstream Partner Session & Industry Ecosystem Co-Creation Session being held on Sept. 29, 2026, at 5:00 p.m. PDT at www.ff.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924635672/en/

Faraday Future Announces Details for Its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two, Upstream Partner & Industry Ecosystem Co-Creation Session to be Held on Sept. 29

Faraday Future Announces Details for Its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two, Upstream Partner & Industry Ecosystem Co-Creation Session to be Held on Sept. 29

Following Part One of the FF EAI Robotics “Built in USA” Upstream & Downstream Business Partner Conference, held in Los Angeles on Aug. 26, Part Two will feature insights from more than 10 partners from around the world, who will share their perspectives on the EAI robotics industry and FF’s “Built in USA” initiative.

During the same period, FF will also participate in IROS 2026 in Pittsburgh, Pennsylvania, from September 28–30.

IROS 2026 – The IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS) is one of the largest and most impactful robotics research conferences worldwide. IROS 2026 will bring together researchers, engineers, and industry leaders in Pittsburgh, a city at the forefront of robotics innovation, home to world-renowned institutions and cutting-edge autonomous vehicle companies.

Visit FF at Booth #932 to experience FF EAI robotics products up close, learn more about the FF EAI Robotics “Built in USA” Acceleration Program and its implementation roadmap, and explore opportunities for collaboration.

Dates: September 28–30, 2026 (ET)

Location: David L. Lawrence Convention Center, booth #932

1000 Fort Duquesne Blvd, Pittsburgh, PA 15222

FF aims to build the world’s only “One-Brain Multi-Form Multi-Capability” FF EAI Robot World. Its “Four-Core Full-Stack AI” ecosystem is taking shape, and Robot World 2.0 is complete. Spanning three robot forms, five series, 11 models and 24 products, FF believes its lineup offers the most complete range of robot forms, broadest size coverage and most models of any U.S. robotics company—providing industries and users with an EAI Brain, solutions and data across those forms.

Note: Event materials will be available on the FF IR website at https://investors.ff.com/events-and-presentations

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a “Four-Core Full-Stack AI” ecosystem of EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and EAI Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible debt investors to fund the Company; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s reliance on Chinese OEMs for all of its robotics products; the possibility of the federal government banning imports of Chinese robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026; the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Technology Vehicle Technology Automotive Automotive Manufacturing Software Manufacturing Hardware Autonomous Driving/Vehicles Robotics Artificial Intelligence

MEDIA:

Photo
Photo
Faraday Future Announces Details for Its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two, Upstream Partner & Industry Ecosystem Co-Creation Session to be Held on Sept. 29
Logo
Logo

ACM Queue Publishes CAFE(S): A Framework for Improving AI Coding Agent Effectiveness

ACM Queue Publishes CAFE(S): A Framework for Improving AI Coding Agent Effectiveness

ACM Queue publishes new research establishing five dimensions of context quality.

TEAM Anywhere/SAN FRANCISCO–(BUSINESS WIRE)–
Atlassian Corporation (NASDAQ: TEAM), a leading provider of AI-powered collaboration and team productivity software, today announced that researchers from DX (a subsidiary of Atlassian Corporation), Capital One, GitHub, the University of Victoria, and Google published CAFE(S), a diagnostic framework designed to evaluate the context provided to AI agents. Published in ACM Queue, the research establishes an industry standard for diagnosing, designing, and maintaining the information environments that power AI coding agents across the software development lifecycle.

As software engineering organizations scale investments in AI coding agents, task failures are often attributed to issues with model capabilities or harness orchestration. However, research demonstrates that even frontier models degrade when provided with ambiguous, incomplete, or stale context.

The CAFE(S) framework introduces a shared diagnostic vocabulary for platform teams, developer productivity leaders, and software engineers to evaluate assembled context across five dimensions:

  1. Clarity: Can the agent interpret the request the way the person intended? Ambiguity is often invisible to the person writing the request. CAFE(S) helps teams ensure the agent understands the work the same way a teammate would.
  2. Actionability: Does the agent have clear goals, useful boundaries, and a way to know when it is done? A request can be clear but still leave out the goal, say too little about the constraints, or give no way to tell that the work is finished.
  3. Fidelity: Is the context true at the moment the agent reads it? Accuracy decays over time. Stale documentation, old architectural decisions, and conflicting sources lead agents down the wrong path.
  4. Efficiency: Is the context scoped to the task, without unnecessary token load? More context is not always better. Passing an entire repository when an agent needs a single function inflates costs and degrades performance.
  5. Security: Should the agent have this context at all? The “S” is kept at a remove because the first four dimensions determine whether context helps the task, whereas security asks if the context is fundamentally appropriate, compliant, and safe to access in the first place.

“AI does not create a new need for good knowledge management; it dramatically increases the cost of poor knowledge management. When agents receive poor context, they are forced to guess. That forces humans to spend their time compensating for avoidable mistakes, creating developer rework, token waste, and reliability risks. CAFE(S) treats context quality as a first-class engineering discipline that teams can deliberately design, evaluate, and maintain.” – Brian Houck, Distinguished Scientist at DX and co-author of the paper

The research emphasizes that capable models alone are insufficient to ensure reliable task completion and stronger delivery outcomes. Teams that systematically strengthen the information environments feeding their agents will see better results. CAFE(S) becomes a quality scorecard for context, designed to sit on top of the existing stack.

What’s next?

This research defines a framework, not a measurement system. Future work will be needed to develop reliable ways of assessing these properties at scale, and to understand how improvements in context quality influence collaboration, software delivery, and organizational outcomes. But meaningful measurement requires a shared definition of what is being measured. Before teams can improve context quality, they need a vocabulary for discussing it.

Download the full research paper: https://getdx.com/report/the-cafes-framework/

About Atlassian

Atlassian unleashes the potential of every team. A recognized leader in software development, work management, and enterprise service management software, Atlassian enables enterprises to connect their business and technology teams with an AI-powered system of work that unlocks productivity at scale. Atlassian’s collaboration software powers over 85% of the Fortune 500 and 350,000+ customers worldwide – including NASA, Rivian, Deutsche Bank, United Airlines, and Bosch – who rely on our solutions to drive work forward.

About DX

DX is an engineering intelligence platform focused on helping organizations understand and improve the systems, workflows, and information environments that shape software delivery. By translating research-backed methodologies into practical organizational metrics, DX helps engineering leaders reduce friction, optimize developer experience, and drive measurable velocity. To learn more, visit getdx.com.

For further information, please contact Atlassian at [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Security Technology Software Networks Artificial Intelligence Internet

MEDIA:

Logo
Logo